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Abstract
INTRODUCTION: Latent autoimmune diabetes in
adults (LADA) is regarded as one of the Insulin-de-
pendent diabetes mellitus that progress slowly. It
gradually became understood since 1970s. The on-
set usually appears in adulthood, the islet autoanti-
bodies are positive and the function of β cell is de-
clined rapidly. The treatment is insulin injection.
CASE PRESENTATION: The case reported followed
is a 37-year-old male patient who was newly diag-
nosed with type 2 diabetes. He abandoned oral hy-
poglycemic agents since they caused stomach in-
disposed. Before visiting, his islet autoantibodies
were detected positive and he had never injected
insulin before. We treated him with traditional Chi-
nese herbals under the guidance of Traditional Chi-
nese Medicine and differentiation, and achieved
fine efficacy.
CONCLUSION: Because the initial presentation of
LADA is similar to Type 2 Diabetes Mellitus and ex-
amination is not in common use, misdiagnosis is
not rare. Once LADA is diagnosed, the therapy
must be adjusted. This case report indicated that
Traditional Chinese Medicine might be an alterna-
tive treatment for LADA.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
Researches reported that the prevalence of Latent auto-
immune diabetes in adults (LADA) in Diabetes Melli-
tus (DM) is between 2%-12%.1-3 The main mechanism
is autoimmune destruction of pancreatic β-cells. The
characteristic appearance is that onset commonly hap-
pens in adulthood and Islet autoantibodies are detected
positive along with the function declination of pancre-
atic β-cells. The progression is relatively slow com-
pared to typical Insulin-dependent diabetes and has
the clinical features of insulin resistance.4 Thus, LADA
is regarded as one special form between Type 1 Diabe-
tes Mellitus (T1DM) and Type 2 Diabetes Mellitus
(T2DM).5 In the casewe report as followed, we used
herbals alone, focused on the autoimmune destruction
of pancreatic β-cells and reversed the Islet autoantibod-
ies from positive.
CASE PRESENTATION
A 48-year-old male patient visited our Endocrinology
clinic because of high blood sugar. Before visited, his
random blood glucose once reached 23.9 mmol/L and
then he was diagnosed with T2DM. He used to take
metformin, acarbose and glimepiride one after another,
but had abandoned them all because of stomach indis-
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posed. Now his Fasting blood-glucose (FBG) is ranged
between 8 to 9 mmol/L controlled by diet and exer-
cise. His Body Mass Index (BMI) was 26.26 kg/m2
(overweight), FBG 8.37 mmol/L, Glycated hemoglo-
bin (HbA1C) 7.7%. Test for insulin autoantibodies: is-
let cell antibodies (ICA) positive, insulin auto antibod-
ies (IAA) positive, glutamic acid decarboxylase anti-
body (GADA) negative. Liver and kidney function,
uric acid and lipids are within normal.
Used Mianyi decoction formed by traditional Chinese
herbals as treatment based on immunity suppression
(one decoction per day, 28 days as one period of treat-
ment): Leigongteng (Radix et Rhizoma Tripterygii)
15 g, Wuweizi (Fructus Schisandra Chinensis) 15 g,
Shenggancao (Radix Glycyrrhizae) 15 g, Gegen (Radix
Puerariae Lobatae) 72 g, Huangqin (Radix Scutellariae
Baicalensis) 27 g, Huanglian (Rhizoma Coptidis) 27 g,
Ganjiang (Rhizoma Zingiberis Recens) 4.5 g, Jixueteng
(Caulis Spatholobi) 30 g, and Chaoduzhong (Cortex Eu-
commiae) 30 g.
The patient visited again after 1-month-treatment.
FBG was 7.57 mmol/L, and HbA1C 6.7%. Liver and
kidney function, uric acid and lipids are within nor-
mal. Test for insulin autoantibodies: ICA positive, IAA
negative, GADA negative. Removed Duzhong (Cortex
Eucommiae) 30 g from last decoction and continued
for another period of treatment. HbA1C decreased to
6.1% after second period of treatment and ICA, IAA
and GADA were all negative. Adjusted the decoction
as followed and continued another period of treat-
ment: Leigongteng (Radix et Rhizoma Tripterygii) 15 g,
Wuweizi (Fructus Schisandra Chinensis) 15 g, Shenggan-
cao (Radix Glycyrrhizae) 15 g, Gegen (Radix Puerariae
Lobatae) 45 g, Huangqin (Radix Scutellariae Baicalen-
sis) 30 g, Huanglian (Rhizoma Coptidis) 30 g, Zhimu
(Rhizoma Anemarrhenae) 30 g, Chishao (Radix Paeoni-
ae Rubra) 30 g, and Shengjiang (Rhizoma Zingiberis Re-
cens) 15 g, After three periods of Traditional Chinese
Medicine (TCM), his insulin autoantibodies reversed
from positive to negative. The patient visits clinic,
takes TCM regularly, and stays in stable condition. Fur-
ther efficacy needs further follow-up.
DISCUSSION
There is considerable proportion of LADA patients be-
ing misdiagnosed since the early appearance is similar
with T2DM and the test of islet autoantibodies is not
widely used. Those who take oral hypoglycemic would
turn into insulin-dependent as the hyposecretion of in-
sulin led by autoimmune destruction of islet β cell.6
LADA has spectacular pathogenesis. Though it express-
es the same islet autoantibodies as T1DM does,7 the an-
tigen HLA-DR4-DQ8 is not widely expressed as in
T1DM. It is the possible reason that LADA progresses
slowly.8 LADA contains both hyposecretion and resis-
tance of insulin. Research had proven that LADA con-
verged the genetic characteristics of T1DM and
T2DM.8 Despite longer period of insulin usage, the
blood sugar of LADA is worse than those of T2DM.9
Thus choosing more adequate treatment for LADA is
still a challenge.
The best treatment for LADA is not only control the
blood sugar, but also protect the remained function ofβ cell from autoimmune destruction.5 Researches indi-
cated that insulin combined with thiazolidinedione
could protect the construction of β cell.10-12 But thia-
zolidinedione might not control blood sugar as well as
other hypoglycemic. Insulin combined with sulfonyl-
urea might have better control on blood sugar,13 but
sulfonylurea is not the first-line drugs since it could de-
plete the function of β cell. Metformin is preferred in
insulin resistance. The treatment for LADA should
based on insulin and adjust the usage of oral hypoglyce-
mic. Besides, autoimmunity must be suppressed as the
autoimmune T cell would attack β cell continuously.
Immunity adjustment must be appropriate to avoid
side affect. Side affect could be deduced by immune
tolerance induced by autoantigen.5
Among those published researches, some used small
doses of insulin to treat LADA patients in a multi-cen-
ter trial, and had positive results.14,15 Yang et al 18 used
Thiazolidinediones which could modulate inflamma-
tion and autoimmunity potentially,16,17 combined with
rosiglitazone and insulin treating LADA patients for
three years, and could protect the function of the pan-
creas. There is report proved that insulin injection
could stabilize the concentration of autoantibodies,19
but still there is article reported that the concentration
of autoantibodies were irreversibly increased under in-
sulin injection.20 Agardh et al 21 treated LADA patients
with alum-formulated recombinant GAD65 (GAD-al-
um) for 5 years and did not observe significant differ-
ence from those who took oral hypoglycemic agents.
Montes et al 22 reported that etanercept could treat LA-
DA patients. But unfortunately, etanercept is not with-
out side effects, as it contains a black box warning for
serious infection risk and development of lymphoma
and other malignancies in children and adolescents. In
the matter of TCM treating LADA, Ouyang et al 23
used tripterygium glycosides combined with oral hypo-
glycemic agents, Lei et al 24 used tripterygium glyco-
sides combined with insulin injection, were both better
than oral hypoglycemic agents or insulin injection. Xu
et al 25 and Hao et al 26 used Chinese herbal combined
with insulin injection and had better efficacy. But there
is no report that using TCM alone to treat LADA.
In this case, the patient could not endure the side ef-
fect of oral hypoglycemic and stop medication. His
blood sugar was beyond control only by diet and exer-
cise. He came to our clinic after islet autoantibodies
were detected positive. We used TCM based on im-
mune suppression as treatment and adjusted the decoc-
tion by differentiation. The decoction, Mianyi decoc-
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tion, is mainly formed by Leigongteng (Radix et Rhi-
zoma Tripterygii), Wuweizi (Fructus Schisandra Chinen-
sis), Shenggancao (Radix glycyrrhizae), could suppress
the T cell to adjust the subsets imbalance and inhibit
the expression of inflammatory mediators to modulat-
ing the immune response.27-30 It is used in autoimmune
diseases such as rheumatoid arthritis and systemic lu-
pus erythematosus.31,32 Researches has reported that
Leigongteng (Radix et Rhizoma Tripterygii) combined
with insulin or oral hypoglycemic was effective to LA-
DA in recent years.27,28 The mechanism might relate to
immune suppression. But the side effects of Leigong-
teng (Radix et Rhizoma Tripterygii) is mainly including
liver damage, gastrointestinal reactions, reproductive
system damage and so on.33,34 The average dosage is
about 15-30 g per day. Wuweizi (Fructus Schisandra
Chinensis) and Shenggancao (Glycyrrhiza uralensis)
could improve the effectiveness of Leigongteng (Radix
et Rhizoma Tripterygii) and deduced its side effects.35-37
The addition of Gegen (Radix Puerariae Lobatae),
Huangqin (Radix Scutellariae Baicalensis), and Huangli-
an (Rhizoma Coptidis) is based on differentiation.38 The
whole decoction can adjust immune system compre-
hensively.
The particularity of this case is that using TCM alone
as treatment and reversed the expression of islet autoan-
tibodies. The adequate compatibility deduced the side
effects of Leigongteng (Radix et Rhizoma Tripterygii)
and enhanced the blood sugar control.
CONCLUSION
LADA, as one of subtypes of Diabetes Mellitus, is an
autoimmune disease. The function of β cell decreases
as autoimmune destruction processing. Our clinic prac-
tice has shown that TCM could reverse the expression
of islet autoantibodies and control blood sugar in an ac-
ceptable range which provides alternative way to cure
LADA.
REFERENCES
1 Hwangbo Y, Kim JT, Kim EK, et al. Prevalence and clini-
cal characteristics of recently diagnosed type 2 diabetes pa-
tients with positive anti-glutamic acid decarboxylase anti-
body. Diabetes Metab J 2012; 36(2): 136-143.
2 Guglielmi C, Palermo A, Pozzilli P. Latent autoimmune
diabetes in the adults (LADA) in Asia: from pathogenesis
and epidemiology to therapy. Diabetes Metab Res Rev
2012; 28(Suppl 2): 40-46.
3 Hawa MI, Kolb H, Schloot N, et al. Adult-onset autoim-
mune diabetes in Europe is prevalent with a broad clinical
phenotype: action LADA 7. Diabetes Care 2013; 36(4):
908-913.
4 Hawa MI, Thivolet C, Mauricio D, et al. Metabolic syn-
drome and autoimmune diabetes: action LADA 3. Diabe-
tes Care 2009; 32(1): 160-164.
5 Cervin C, Lyssenko V, Bakhtadze E, et al. Genetic similar-
ities between latent autoimmune diabetes in adults, type 1
diabetes, and type 2 diabetes. Diabetes 2008; 57(5): 1433-
1437.
6 Lee SA, Kim EY, Kim EH, et al. Anti-GAD antibody in
patients with adult-onset diabetes in Korea. Korean Diabe-
tes J 2009; 33(1): 16-23.
7 Radtke MA, Midthjell K, Nilsen TI, et al. Heterogeneity
of patients with latent autoimmune diabetes in adults:
linkage to autoimmunity is apparent only in those with
perceived need for insulin treatment: results from the
Nord-Trøndelag Health (HUNT) study. Diabetes Care
2009; 32(2): 245-250.
8 Schranz DB, Bekris L, Landin-Olsson M, et al. Newly di-
agnosed latent autoimmune diabetes in adults (LADA) is
associated with low level glutamate decarboxylase
(GAD65) and IA-2 autoantibodies. Diabetes incidence
study in Sweden (DISS). Horm Metab Res 2000; 32(4):
133-138.
9 Andersen CD, Bennet L, Nyström L, et al. Worse glycae-
mic control in LADA patients than in those with type 2 di-
abetes, despite a longer time on insulin therapy. Diabetolo-
gia 2013; 56(2): 252-258.
10 Tiittanen M, Huupponen JT, Knip M, et al. Insulin treat-
ment in patients with type 1 diabetes induces upregulation
of regulatory T-cell markers in peripheral blood mononu-
clear cells stimulated with insulin in vitro. Diabetes 2006;
55(12): 3446-3454.
11 Holloway AC, Petrik JJ, Bruin JE, et al. Rosiglitazone pre-
vents diabetes by increasing beta-cell mass in an animal
model of type 2 diabetes characterized by reduced beta-cell
mass at birth. Diabetes Obes Metab 2008; 10(9): 763-
771.
12 Ghanaat-Pour H, Sjoholm A. Gene expression regulated
by pioglitazone and exenatide in normal and diabetic rat is-
lets exposed to lipotoxicity. Diabetes Metab Res Rev 2009;
25(2): 163-184.
13 Maruyama T, Tanaka S, Shimada A, et al. Insulin inter-
vention in slowly progressive insulin-dependent (type 1)
diabetes mellitus. J Clin Endocrinol Metab 2008; 93(6):
2115-2121.
14 Maruyama T, Shimada A, Kanatsuka A, et al. Multicenter
prevention trial of slowly progressive IDDM with small
dose of insulin (the Tokyo Study). Ann N Y Acad Sci
2003; 1005: 362-369.
15 Kobayashi T, Maruyama T, Shimada A, et al. Insulin in-
tervention to preserve β cells in slowly progressive insu-
lin-dependent (type 1) diabetes mellitus. Ann NY Acad
Sci 2002; 958: 117-130.
16 Cuzzocrea S, Pisano B, Dugo L, et al. Rosiglitazone, a li-
gand of the peroxisome proliferator-activated receptor-g,
reduces acute inflammation. Eur J Pharmacol 2004; 483:
79-93.
17 Mohanty P, Aljada A, Ghanim H, et al. Evidence for a po-
tent anti-inflammatory effect of rosiglitazone. J Clin Endo-
crinol Metab 2004; 89(6): 2728-2735.
18 Yang Z, Zhou Z, Li X, et al. Rosiglitazone preserves islet
β-cell function of adult-onset latent autoimmune diabetes
in 3 years follow-up study. Diabetes Res Clin Pract 2009;
83(1): 54-60.
768
JTCM |www. journaltcm. com December 15, 2013 |Volume 33 | Issue 6 |
Tian JX et al. / Clinical Study
19 Vieira Filho JP, Moisés RC, de Sá JR, et al. Latent autoim-
mune diabetes of the adult (LADA) in a Brazilian Indian.
Sao Paulo Med J 2001; 119(2): 84-85.
20 Ray S, Sarkar D, Ganguly S, et al. An unusual presenta-
tion of latent autoimmune diabetesin adults. Med J Malay-
sia 2012; 67(1): 116-117.
21 Agardh CD, Lynch KF, Palmér M, et al. GAD65 vaccina-
tion: 5 years of follow-up in a randomised dose-escalating
study in adult-onset autoimmune diabetes. Diabetologia
2009; 52(7): 1363-1368.
22 Montes VN, Hirsch IB. Treatment of LADA with etaner-
cept. Diabetes Care 2012; 35(5): e36.
23 Ouyang LL, Zhou ZG, Peng J, et al. Preliminary clinical
study on tripterygium intervention in LADA patients.
Zhong Guo Tang Niao Bing Za Zhi 2000; 8(1): 7-9.
24 Lei T, Zhang XZ, He M, et al. Effect of multi-glycosides
of tripterygii on latent autoimmune diabetes in adults in
early stage. Zhong Guo Zhong Xi Yi Jie He Za Zhi 2006;
26(6): 511-513.
25 Xu XW, Zhang DX, Bai CY. Clinical study on Tan-
gyikang for adults autoimmune diabetes mellitus. Zhong
Hua Zhong Yi Yao Xue Kan 2009, 27(1): 174-176.
26 Hao P, Ji XS, Tan DY, et al. The influenc from Tangmai-
kang to the LADA patients' application of insulin. Chang-
chun Zhong Yi Xue Yuan Xue Bao 1998; 14(9): 16.
27 Li YF, Hong P, Li X, et al. The effect of tripterygium gly-
cosides on T lymphocyte subsets. Zhong Hua Wei Sheng
Wu Xue He Mian Yi Xue Za Zhi 2001; 21(1): 69.
28 Tang W, Zuo JP. Immunosuppressant discovery from
Tripterygium wilfordii Hook f: the novel triptolide analog
(5R)-5-hydroxytriptolide (LLDT-8). Acta Pharmacol Sin
2012; 33(9): 1112-1118.
29 Chen BJ. Triptolide, a novel immunosuppressive and an-
ti-inflammatory agent purified from a Chinese herb Tripte-
rygium wilfordii Hook F. Leuk Lymphoma 2001; 42(3):
253-265.
30 Ma J, Dey M, Yang H, et al. Anti-inflammatory and im-
munosuppressive compounds from Tripterygium wilfordii.
Phytochemistry 2007; 68(8): 1172-1178.
31 Bao J, Dai SM. A Chinese herb Tripterygium wilfordii
Hook F in the treatment of rheumatoid arthritis: mecha-
nism, efficacy, and safety. Rheumatol Int 2011; 31(9):
1123-1129.
32 Patavino T, Brady DM. Natural medicine and nutritional
therapy as an alternative treatment in systemic lupus ery-
thematosus. Altern Med Rev 2001; 6(5): 460-471.
33 Li J, Huang D, He LQ. Effects of glycosides of tripterygi-
um wilfordii and cistanche deserticola on the fertility of
male mice. Zhong Hua Nan Ke Xue 2009; 15(6):
569-572.
34 Xue X, Gong L, Qi X, et al. Knockout of hepatic P450 re-
ductase aggravates triptolide-induced toxicity. Toxicol Lett
2011; 205(1): 47-54.
35 Takimoto Y, Qian HY, Yoshigai E, et al. Gomisin N in
the herbal drug gomishi (Schisandra chinensis) suppresses
inducible nitric oxide synthase gene via C/EBPβ and
NF-κB in rat hepatocytes. Nitric Oxide 2013; 28: 47-56.
36 Yan F, Zhang QY, Jiao L, et al. Synergistic hepatoprotec-
tive effect of Schisandrae lignans with Astragalus polysac-
charides on chronic liver injury in rats. Phytomedicine
2009; 16(9): 805-813.
37 Li YS, Tong PJ, Ma HZ, et al. Toxicity attenuation and ef-
ficacy potentiation effect of Liquorice on treatment of
rheumatoid arthritis with tripterygium wilfordii. Zhong
Guo Zhong Xi Yi Jie He Za Zhi 2006; 26(12):
1117-1119.
38 Tong XL, Zhao LH, Lian FM, et al. Clinical observations
on the dose-effect relationship of Gegen Qinlian decoc-
tion on 54 Out-patients with Type 2 Diabetes. J Tradit
Chin Med 2011; 31(1): 56-59.
769
